Literature DB >> 16435095

[Current morphological diagnosis of malignant lung tumors].

K Junker1.   

Abstract

The histological classification of lung tumors is based upon the 2004 WHO classification. Small cell lung cancer (SCLC) is primarily treated by means of anti-neoplastic chemotherapy, independently of the tumor stage. In resectable stages of non-small cell lung cancer (NSCLC, UICC-stages I and II), complete tumor resection is the aim. Therefore, the distinction between SCLC and NSCLC is still of particular importance. Currently, great interest is focused on the identification of specific therapeutic targets, especially on the inhibition of the epidermal growth factor ruptur (EGFR). Today, malignant lung tumors can also be classified by means of molecular pathology. Subgroups with different prognoses can be identified by gene expression profiling. The expression levels of several genes are associated with sensitivity against certain anti-cancer agents.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16435095     DOI: 10.1007/s00292-006-0818-1

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  15 in total

1.  Molecular characteristics of non-small cell lung cancer.

Authors:  M Nacht; T Dracheva; Y Gao; T Fujii; Y Chen; A Player; V Akmaev; B Cook; M Dufault; M Zhang; W Zhang; M Guo; J Curran; S Han; D Sidransky; K Buetow; S L Madden; J Jen
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

2.  Expression profiles of non-small cell lung cancers on cDNA microarrays: identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs.

Authors:  Takefumi Kikuchi; Yataro Daigo; Toyomasa Katagiri; Tatsuhiko Tsunoda; Koichi Okada; Soji Kakiuchi; Hitoshi Zembutsu; Yoichi Furukawa; Masafumi Kawamura; Koichi Kobayashi; Kohzoh Imai; Yusuke Nakamura
Journal:  Oncogene       Date:  2003-04-10       Impact factor: 9.867

3.  Erlotinib in lung cancer - molecular and clinical predictors of outcome.

Authors:  Ming-Sound Tsao; Akira Sakurada; Jean-Claude Cutz; Chang-Qi Zhu; Suzanne Kamel-Reid; Jeremy Squire; Ian Lorimer; Tong Zhang; Ni Liu; Manijeh Daneshmand; Paula Marrano; Gilda da Cunha Santos; Alain Lagarde; Frank Richardson; Lesley Seymour; Marlo Whitehead; Keyue Ding; Joseph Pater; Frances A Shepherd
Journal:  N Engl J Med       Date:  2005-07-14       Impact factor: 91.245

Review 4.  Molecular genetic tumor markers in non-small cell lung cancer.

Authors:  Tsunehiro Oyama; Toshihiro Osaki; Tetsuro Baba; Yoshika Nagata; Makiko Mizukami; Tetsuya So; Shoji Nakata; Yoshinobu Ichiki; Hidetaka Uramoto; Masakazu Sugaya; Takashi Yoshimatsu; Masaru Morita; Takeshi Hanagiri; Kenji Sugio; Toshihiro Kawamoto; Kosei Yasumoto
Journal:  Anticancer Res       Date:  2005 Mar-Apr       Impact factor: 2.480

5.  EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Authors:  J Guillermo Paez; Pasi A Jänne; Jeffrey C Lee; Sean Tracy; Heidi Greulich; Stacey Gabriel; Paula Herman; Frederic J Kaye; Neal Lindeman; Titus J Boggon; Katsuhiko Naoki; Hidefumi Sasaki; Yoshitaka Fujii; Michael J Eck; William R Sellers; Bruce E Johnson; Matthew Meyerson
Journal:  Science       Date:  2004-04-29       Impact factor: 47.728

6.  Trends in histopathology of lung cancer in Alberta.

Authors:  Juanita Hatcher; Douglas C Dover
Journal:  Can J Public Health       Date:  2003 Jul-Aug

7.  [Therapy-induced morphological changes in lung cancer].

Authors:  K Junker
Journal:  Pathologe       Date:  2004-11       Impact factor: 1.011

Review 8.  The changing epidemiology of lung cancer in Europe.

Authors:  Maryska L G Janssen-Heijnen; Jan-Willem W Coebergh
Journal:  Lung Cancer       Date:  2003-09       Impact factor: 5.705

9.  Gene expression-based, individualized outcome prediction for surgically treated lung cancer patients.

Authors:  Shuta Tomida; Katsumi Koshikawa; Yasushi Yatabe; Tomoko Harano; Nobuhiko Ogura; Tetsuya Mitsudomi; Masato Some; Kiyoshi Yanagisawa; Toshitada Takahashi; Hirotaka Osada; Takashi Takahashi
Journal:  Oncogene       Date:  2004-07-08       Impact factor: 9.867

10.  Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.

Authors:  Fred R Hirsch; Marileila Varella-Garcia; Paul A Bunn; Michael V Di Maria; Robert Veve; Roy M Bremmes; Anna E Barón; Chan Zeng; Wilbur A Franklin
Journal:  J Clin Oncol       Date:  2003-09-02       Impact factor: 44.544

View more
  1 in total

1.  [Small cell lung cancer: pathology and molecular pathology].

Authors:  K Junker; I Petersen
Journal:  Pathologe       Date:  2009-03       Impact factor: 1.011

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.